Ueda H - Search Results

1

High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter.

Ikeda M, Koh Y, Oyanagi J, Teraoka S, Ishige M, Fujimura Y, Takeda K, Tokudome N, Ozawa Y, Ueda H, Yamamoto N. Ikeda M, et al. Among authors: ueda h. Anticancer Res. 2022 Jan;42(1):407-417. doi: 10.21873/anticanres.15499. Anticancer Res. 2022. PMID: 34969751

2

Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer.

Kikuchi T, Akamatsu H, Mori K, Tanaka A, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Nakanishi M, Ueda H, Yamamoto N. Kikuchi T, et al. Among authors: ueda h. Respir Investig. 2016 Nov;54(6):479-483. doi: 10.1016/j.resinv.2016.05.007. Epub 2016 Jul 16. Respir Investig. 2016. PMID: 27886861

3

Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.

Yagi S, Koh Y, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Endo K, Nakamura S, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N. Yagi S, et al. Among authors: ueda h. PLoS One. 2017 Jun 22;12(6):e0179744. doi: 10.1371/journal.pone.0179744. eCollection 2017. PLoS One. 2017. PMID: 28640869 Free PMC article.

4

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Sato K, et al. Among authors: ueda h. Lung Cancer. 2018 Jan;115:71-74. doi: 10.1016/j.lungcan.2017.11.019. Epub 2017 Nov 21. Lung Cancer. 2018. PMID: 29290265 Free article.

5

Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Sato K, et al. Among authors: ueda h. Lung Cancer. 2018 Dec;126:230-231. doi: 10.1016/j.lungcan.2018.11.007. Epub 2018 Nov 18. Lung Cancer. 2018. PMID: 30459086 Free article. No abstract available.

6

Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.

Koh Y, Yagi S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N. Koh Y, et al. Among authors: ueda h. Clin Lung Cancer. 2019 Jul;20(4):270-277.e1. doi: 10.1016/j.cllc.2019.03.004. Epub 2019 Mar 25. Clin Lung Cancer. 2019. PMID: 31005568 Free article.

7

Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.

Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Among authors: ueda h. Lung Cancer. 2019 Jun;132:107-113. doi: 10.1016/j.lungcan.2019.03.020. Epub 2019 Mar 22. Lung Cancer. 2019. PMID: 31097082

8

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system.

Ikeda M, Koh Y, Teraoka S, Sato K, Kanai K, Hayata A, Tokudome N, Akamatsu H, Ozawa Y, Akamatsu K, Endo K, Higuchi M, Nakanishi M, Ueda H, Yamamoto N. Ikeda M, et al. Among authors: ueda h. Cancer Med. 2020 Mar;9(6):2122-2133. doi: 10.1002/cam4.2846. Epub 2020 Jan 30. Cancer Med. 2020. PMID: 31999390 Free PMC article.

9

CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: ueda h. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.

10

Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.

Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Among authors: ueda h. Clin Lung Cancer. 2021 Nov;22(6):e833-e841. doi: 10.1016/j.cllc.2021.04.007. Epub 2021 Apr 27. Clin Lung Cancer. 2021. PMID: 34049821 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,279 results

Search Page